Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver diseaseZoe Boyer‐Díaz, Jordi Gracia‐Sancho, Pierre Broqua et al.|Journal of Hepatology|2020Cited by 163
Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertensionPeio Aristu-Zabalza, Jordi Gracia‐Sancho, María Andrés‐Rozas et al.|Biology of Sex Differences|2025Cited by 8
GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASHMaría Andrés‐Rozas, Jordi Gracia‐Sancho, Eugènia Ruiz-Cánovas et al.|JHEP Reports|2025Cited by 2
Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertension Peio Aristu-Zabalza, Jordi Gracia‐Sancho, María Andrés‐Rozas et al.|Research Square|2025Cited by 0